News and Events
Researchers discover the multiple shapes of RNA, a boon for drug design
Using atomic force microscopy, CCR researchers directly observed individual RNA structures in cell-like conditions. They found that one primary RNA sequence can fold into many different conformations, which has important implications for the fundamental understanding of RNA and RNA-targeted drug design.
Read More
Scientists repurpose HPV vaccine technology to fight eye cancer
Uveal melanoma is a rare eye cancer that affects about 1,600 people in the United States. A study by scientists in the Center for Cancer Research and Aura Biosciences, Cambridge, Mass., published December 14, 2017, in Molecular Cancer Therapeutics, provides new hope for the early treatment of uveal melanoma. Read more…
Read More
Mark Roschewski discusses significance of early detection in solid tumors with Newsweek
A recent Newsweek article profiles the capabilities of CancerSEEK, a blood-based cancer detection test that may improve detection of early-stage cancers, including those that are hard to detect. Mark Roschewski, M.D., Staff Clinician in the Lymphoid Malignancies Branch, offered insight on the value of early detection for patients with solid tumors, such as those of the pancreas. According to Dr. Roschewski, “In solid tumors, earlier detection is actually the key. The earlier that one could detect a patient with a tumor, the more likely that the intervention would succeed because the intervention is surgery.” Read the full article…
Read More
Combination therapy for non-small cell lung cancer studied in new clinical trial
Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is slow growing and can affect smokers and non-smokers alike. David S. Schrump, M.D., Surgical Chief of the Thoracic and Gastrointestinal Oncology Branch, is leading the NCI’s participation in a multicenter trial of a combination drug therapy in patients with NSCLC. Read more...
Read More
Yves Pommier named fellow of the American Association for the Advancement of Science
Yves Pommier, M.D., Ph.D., Chief of the Developmental Therapeutics Branch, was recently elected a fellow of the American Association for the Advancement of Science (AAAS). Election as a fellow honors AAAS members whose efforts to advance science or its applications have distinguished them among their peers and colleagues. The 2017 AAAS Fellows will be recognized on Feb. 17, 2018 at the AAAS annual meeting in Austin, TX. Read more...
Read More
Michael Gottesman honored with Order of the Rising Sun by Japanese Government
The Government of Japan recently honored Michael Gottesman, M.D., Chief of the Laboratory of Cell Biology, with the Order of the Rising Sun, Gold Rays and Neck Ribbon, for his contributions toward promoting research exchange in the biomedical field between the U.S. and Japan. The Order of the Rising Sun was established in 1875 as the first national decoration awarded by the Japanese government. Read more...
Read More
New NCI video showcases one patient’s clinical-trial journey
Sue Scott was diagnosed with cervical cancer in 2011. When standard treatment failed to eliminate her cancer cells, Scott’s doctor referred her to an immunotherapy clinical trial at the National Cancer Institute (NCI) with Christian Hinrichs, M.D., Investigator and Lasker Scholar in CCR’s Experimental Transplantation and Immunology Branch. Immunotherapy is a type of cancer treatment where the patient’s own immune system is used to fight the cancer. In this video, Sue details her story of survival and experience of taking part in a clinical trial with CCR. Watch the video here.
Read More
Natalie Porat-Shliom joins CCR as NIH Stadtman Investigator
Natalie Porat-Shliom, Ph.D. has joined the Thoracic and Gastrointestinal Oncology Branch (TGIB) as a Stadtman Tenure Track Investigator. Dr. Porat-Shliom's research focuses on utilizing intravital microscopy for imaging and understanding the biology of human cancer. She will explore how normal and malignant cells metabolically adapt to changes in nutrient supply and energy demand and will address specific questions concerning metabolic heterogeneity under physiological conditions and metastatic disease using both mouse model and human samples. Learn more...
Read More
NBC4 interviews Foregut Team stomach-removal patient
The CDH1 gene mutation elevates an individual’s lifetime risk of developing stomach cancer to 60-70 percent. Total gastrectomy, or complete removal of the stomach, is a preventive option for persons with this anomaly. After receiving a positive result for the gene mutation at age 40, David Fogel began researching his options and decided to enroll in a clinical trial at the National Institutes of Health led by Jeremy Davis, M.D., Staff Clinician in the Thoracic and Gastrointestinal Oncology Branch. As part of the trial, which aims to study the effects of stomach removal for patients with the CDH1 gene mutation, Fogel had his stomach removed in October 2017. In a recent interview with Washington’s NBC4, Fogel discussed life without a stomach with a fellow Maryland resident who also underwent a total gastrectomy after testing positive for the CDH1 mutation. Watch the video here.
Read More
Foregut team stomach-removal patient featured in The Washington Post
Individuals with the CDH1 gene mutation have an increased risk of developing stomach cancer. Over the last two decades, total gastrectomy, or removal of the stomach, has become an extreme preventive option for those with the CDH1 mutation. After testing positive for the mutation at age 40, David Fogel began researching his options and decided to enroll in a clinical trial at the National Institutes of Health led by Jeremy Davis, M.D., Staff Clinician in the Thoracic and Gastrointestinal Oncology Branch. As part of the trial, which aims to study the effects of stomach removal for patients with the CDH1 gene mutation, Fogel had his stomach completely removed in October 2017. Now months later, Fogel is in high spirits and has no regrets. Read the full story here.
Read More